1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,000 | 8,400 | 30.04. | |
| 8,000 | 8,400 | 30.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| Mi | KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ... | 1 | HKEx | ||
| Mi | KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| Mi | KEYMED BIO-B (02162): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 15.04. | KEYMED BIO-B (02162): SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | - | HKEx | ||
| 02.04. | A Healthy Return: Drug Spin-off Nets Keymed Up To $320M | 2 | Benzinga.com | ||
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.03. | Keymed Biosciences Announces 2025 Annual Results and Business Updates | 271 | PR Newswire | BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results.
Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year... ► Artikel lesen | |
| 26.03. | KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 23.03. | KEYMED BIO-B (02162): DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | 1 | HKEx | ||
| 16.03. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | - | HKEx | ||
| 10.03. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901) | - | HKEx | ||
| 03.11.25 | Goldman Sachs initiates Keymed Biosciences stock with Buy rating | 1 | Investing.com | ||
| 03.11.25 | Goldman Sachs: Kaufempfehlung für Keymed Biosciences zum Start der Analyse | - | Investing.com Deutsch | ||
| 27.08.25 | Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum | 329 | PR Newswire |
CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.
Financially... ► Artikel lesen | |
| 13.06.25 | Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine | 883 | PR Newswire | CHENGDU, China, June 13, 2025 /PRNewswire/ -- On June 12, Keymed Biosciences Inc. (HKEX: 02162) announced that Prof. Jun Shi's research team from the Institute of Hematology and Blood Diseases... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| OCUGEN | 1,468 | -0,68 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,600 | -3,58 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INFLARX | 1,790 | +1,24 % | InflaRx N.V.: InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement | JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the "Company")... ► Artikel lesen | |
| EDITAS MEDICINE | 2,510 | -1,95 % | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | ||
| SAREPTA THERAPEUTICS | 17,960 | +0,90 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| CARDIOL THERAPEUTICS | 1,152 | -0,86 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| BASILEA | 57,10 | -3,87 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 61,20 | -2,27 % | JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating | ||
| TELIX PHARMACEUTICALS | 9,300 | -0,90 % | Telix Pharmaceuticals Limited: TLX101-Px (Pixlumi) MAA Accepted in Europe | MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,757 | -1,05 % | EQS-Media: Attraktive Chance-Risiko-Konstellation? Onco-Innovations gibt erfolgreiches Scale-up bekannt | EQS-Media / 29.04.2026 / 12:18 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ), Onco oder das Unternehmen, gab unter Bezugnahme auf seine Pressemitteilung vom 21. April 2026... ► Artikel lesen | |
| TWIST BIOSCIENCE | 51,22 | +2,95 % | Twist Bioscience Q2 2026 Earnings Preview | ||
| REPLIGEN | 96,98 | -3,79 % | Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1 | ||
| UNIQURE | 16,640 | -2,12 % | uniQure Inc.: uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease | ~ Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~
~ Type B Meeting with U.S. FDA granted in second quarter; expect to discuss potential... ► Artikel lesen | |
| PHARMAMAR | 96,45 | +0,36 % | PHARMA MAR, S.A.: The Company files first quarter 2026 financial information. |
KEYMED BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,26 % bei einem Aktienkurs von 8,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.